Marker Therapeutics (Nasdaq:MRKR) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MRKR 주식 개요

임상 단계의 면역 종양학 회사인 마커 테라퓨틱스는 혈액암 및 고형 종양 적응증 치료를 위한 새로운 T 세포 기반 면역 요법의 개발 및 상용화에 종사하고 있습니다.

MRKR 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	2/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

수익은 연간 61.22% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 44.7% 증가했습니다.

위험 분석

수익은 향후 3년간 연평균 17.2% 씩 감소할 것으로 예상됩니다.

cash runway 경력이 1년 미만입니다.

최근 3개월간 주가 변동성

의미 있는 수익이 없습니다. ( $3M )

+ 2 더 많은 위험

Marker Therapeutics, Inc. 경쟁사

Aligos Therapeutics

NasdaqCM:ALGS

US$33.5m

Aadi Bioscience

NasdaqCM:AADI

US$43.0m

MDxHealth

NasdaqCM:MDXH

US$69.9m

LAVA Therapeutics

NasdaqGS:LVTX

US$49.2m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Marker Therapeutics
과거 주가
현재 주가	US$4.64
52주 최고치	US$9.68
52주 최저치	US$2.40
베타	1.6
11개월 변경	12.08%
3개월 변경 사항	7.04%
1년 변경 사항	16.29%
33년 변화	-84.48%
5년 변화	-94.10%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Oct 04

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Sep 13

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Aug 11

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Jun 17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Mar 04

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Nov 19

Marker Therapeutics: Passing Through A Catalyst Desert

Oct 22

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Aug 17

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

May 04

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Feb 22

Marker shares rise as it completes construction of its cGMP manufacturing facility

Jan 13

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Jan 05

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Dec 29

Marker Therapeutics EPS misses by $0.02

Nov 09

주주 수익률

	MRKR	US Biotechs	US 마켓
7D	0.4%	2.0%	-0.3%
1Y	16.3%	12.4%	22.3%

수익률 대 산업: MRKR 지난 1년 동안 9.9 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: MRKR 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is MRKR's price volatile compared to industry and market?
MRKR volatility
MRKR Average Weekly Movement	10.3%
Biotechs Industry Average Movement	10.5%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.9%

안정적인 주가: MRKR 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: MRKR 의 주간 변동성은 지난 1년 동안 17% 에서 10% 로 감소했지만 여전히 US 주식의 75%보다 높습니다.

회사 소개

설립	직원	CEO	웹사이트
n/a	8	Juan Vera	markertherapeutics.com

임상 단계 면역 종양학 회사인 마커 테라퓨틱스는 혈액암 및 고형 종양 적응증 치료를 위한 새로운 T 세포 기반 면역 요법의 개발 및 상용화에 종사하고 있습니다. 회사의 다중 종양 관련 항원 특이적 T 세포 기술은 여러 종양 관련 항원을 인식하는 비공학 종양 특이적 T 세포의 제조를 기반으로 합니다. 이 회사는 또한 급성 골수성 백혈병 치료를 위한 MT-401-OTS와 림프종 및 췌장암 치료를 위한 MT-601을 개발하고 있습니다.

Marker Therapeutics, Inc. 기본 사항 요약

Marker Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
MRKR 기본 통계
시가총액	US$42.01m
수익(TTM)	-US$12.21m
수익(TTM)	US$3.32m

12.5x

P/S 비율

-3.4x

P/E 비율

MRKR 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
MRKR 손익 계산서(TTM)
수익	US$3.32m
수익 비용	US$9.62m
총 이익	-US$6.29m
기타 비용	US$5.92m
수익	-US$12.21m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.37
총 마진	-189.54%
순이익 마진	-367.79%
부채/자본 비율	0%

MRKR 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

MRKR 주식 개요

보상

위험 분석

Marker Therapeutics, Inc. 경쟁사

NasdaqCM:ALGS

US$33.5m

NasdaqCM:AADI

US$43.0m

NasdaqCM:MDXH

US$69.9m

NasdaqGS:LVTX

US$49.2m

가격 내역 및 성능

최근 뉴스 및 업데이트

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.48 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: US$1.59 loss per share (vs US$3.58 loss in FY 2022)

Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Recent updates

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.48 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: US$1.59 loss per share (vs US$3.58 loss in FY 2022)

Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

New major risk - Share price stability

Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study

Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse

Second quarter 2023 earnings released: US$0.47 loss per share (vs US$1.11 loss in 2Q 2022)

Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen (Multitaa)-Specific T Cell Product Candidate, Mt-401

Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration

Marker Therapeutics, Inc. Reports Pre-Clinical Data of Its MT-601 multiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics, Inc. Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLC

Marker Therapeutics Announces U.S. Food and Drug Administration Clearance of IND for MT-601, Its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

Consensus revenue estimates increase by 277%

Price target decreased to US$2.17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Resignation of Anthony Kim as Chief Financial Officer, Effective September 30, 2022

Marker Therapeutics Wins $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 Artemis Trial of Mt-401 in Post-Transplant AML

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Nasdaq Grants an Additional 180-Calendar Day Compliance Period to Marker Therapeutics to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 41%

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Marker Therapeutics, Inc. Announces FDA Clearance of IND for Mt-601, the Six-Antigen Targeted T Cell Therapy for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Price target decreased to US$3.63

Marker Therapeutics, Inc., Annual General Meeting, May 24, 2022

Marker Therapeutics, Inc. Announces Frederick Wasserman Will Not Stand for Reelection as Director

Full year 2021 earnings: EPS misses analyst expectations

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Clinical Program Updates and Pipeline Expansion

Price target decreased to US$5.63

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from Russell 3000E Value Index

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Earnings beat expectations, revenue disappoints

Marker Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Trial of Mt-401 in Acute Myeloid Leukemia Following Stem Cell Transplant

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

New 90-day high: US$3.19

Marker shares rise as it completes construction of its cGMP manufacturing facility

New 90-day high: US$1.79

Marker Therapeutics, Inc. Announces U.S. Food and Drug Administration Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

New 90-day high: US$1.75

Earnings beat expectations

Marker Therapeutics EPS misses by $0.02

New 90-day low: US$1.43

New 90-day low: US$1.50

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from S&P Global BMI Index

New 90-day low - US$1.65

주주 수익률